title: Hydroxyethyl starch 200/0.5 decreases circulating tumor cells of colorectal cancer patients and reduces metastatic potential of colon cancer cell line through inhibiting platelets activation.
abstract: Platelets play an important role in metastasis of circulating tumor cells (CTCs). It has been demonstrated that hydroxyethyl starch (HES) inhibits platelets function. However, the effect of HES on CTCs in patients with colorectal cancer remains unclear. We compared the effects of HES 200/0.5 and HES 130/0.4 on CTCs and platelets activation of colorectal patients in this study. Additionally, the effects of HES 200/0.5 or HES 130/0.4 on metastasis ability of colon cancer cell line that stimulated by activated platelets have been explored. In vivo, 90 patients undergoing colorectal cancer radical surgery received randomly 15 mL/kg of HES 200/0.5 (n = 45) or HES 130/0.4 (n = 45) infusion before surgery. Platelet glycoprotein IIb/IIIa (GPIIb/IIIa), CD62P and platelets aggregation rate (PAR) were evaluated pre-, intra- and postoperatively. Cytokeratin-20 (CK-20) mRNA was detected by reverse transcriptase polymerase chain reaction before and after surgery. In vitro, colon cancer SW480 cells were incubated with activated platelets in the presence or absence HES 200/0.5 or HES 130/0.4. The metastasis ability of SW480 cells was assessed by Transwell assay. The results showed that CK-20 mRNA positive rate in HES 200/0.5 group after surgery was decreased significantly as compared to group HES 130/0.4 (χ (2) = 6.164, P = 0.013). Simultaneously, a more pronounced inhibition of platelets activation was observed in group HES 200/0.5. A positive correlation between platelets activation marker and CK-20 mRNA positive rate was found. In vitro, HES 200/0.5, but not HES 130/0.4, decreased the invasion and migration ability of SW480 cells that induced by activated platelets. Besides, the expression of GPIIb/IIIa, CD62P and PAR was inhibited more strongly in group HES 200/0.5 than those in group HES 130/0.4. In summary, we found that HES 200/0.5 significantly decreased CTCs of patients undergoing colorectal cancer radical surgery as compared to HES 130/0.4, which might be associated with inhibiting platelets activation of HES 200/0.5. Furthermore, HES 200/0.5, but not HES 130/0.4, reduced the metastatic potential of colon cell line stimulated by activated platelets through depressing platelets activation. Modulation of platelets activity may be a novel strategy to minimize the risk of metastasis during surgery.
authors.affiliation: Department of Anesthesiology, Affiliated FoShan Hospital of SUN YAT-SEN University, Foshan, 528000, China, lhlh2003@126.com.
authors.forename: Hua
authors.initials: H
authors.lastname: Liang
authors.forename: Chengxiang
authors.initials: C
authors.lastname: Yang
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.forename: Hanbing
authors.initials: H
authors.lastname: Wang
authors.forename: Hongzhen
authors.initials: H
authors.lastname: Liu
authors.forename: Zhenlong
authors.initials: Z
authors.lastname: Zhao
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Zhang
authors.forename: Xianjie
authors.initials: X
authors.lastname: Wen
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Lai
mesh_terms: D001792:Blood Platelets / Q000187:drug effects*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000097:blood* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000031:analogs & derivatives* / Q000494:pharmacology; D053554:Keratin-20 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000473:pathology; D009362:Neoplasm Metastasis / Q000235:genetics / Q000473:pathology*; D009360:Neoplastic Cells, Circulating / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010974:Platelet Aggregation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D053554:Keratin-20; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D012333:RNA, Messenger; C517718:hydroxyethylstarch 200
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53
references.pmid: 17932341
references.citation: CA Cancer J Clin. 2012 Sep-Oct;62(5):283-98
references.pmid: 22987332
references.citation: PLoS One. 2014 Nov 06;9(11):e112005
references.pmid: 25375219
references.citation: Anesthesiology. 2006 Oct;105(4):660-4
references.pmid: 17006061
references.citation: Nat Med. 2006 Aug;12(8):895-904
references.pmid: 16892035
references.citation: PLoS One. 2014 Apr 03;9(4):e93756
references.pmid: 24699879
references.citation: Ann Surg. 2002 Dec;236(6):768-75; discussion 775-6
references.pmid: 12454515
references.citation: Anesthesiology. 2006 Dec;105(6):1228-37
references.pmid: 17122586
references.citation: Eur Urol. 2001 May;39(5):507-15; discussion 516-7
references.pmid: 11464030
references.citation: Anticancer Res. 2013 Sep;33(9):3905-10
references.pmid: 24023327
references.citation: Ann Surg Oncol. 2013 Jul;20(7):2156-65
references.pmid: 23456317
references.citation: Int J Cancer. 2011 Oct 1;129(7):1651-60
references.pmid: 21128227
references.citation: Brain Behav Immun. 2013 Mar;30 Suppl:S32-40
references.pmid: 22504092
references.citation: Int J Clin Oncol. 2006 Oct;11(5):385-9
references.pmid: 17058136
references.citation: Br J Cancer. 2010 Apr 27;102(9):1327-34
references.pmid: 20389297
references.citation: Surgery. 2014 Jan;155(1):134-44
references.pmid: 24238121
references.citation: J Gastrointestin Liver Dis. 2014 Sep;23(3):279-84
references.pmid: 25267956
references.citation: Cancer Biol Ther. 2011 Apr 1;11(7):633-8
references.pmid: 21307656
references.citation: Eur J Anaesthesiol. 2004 Apr;21(4):309-13
references.pmid: 15109195
references.citation: Ann Surg Oncol. 2012 Jun;19(6):2060-5
references.pmid: 21732137
references.citation: Anticancer Res. 2013 May;33(5):2239-43
references.pmid: 23645782
references.citation: Cancer Lett. 2015 Mar 1;358(1):43-6
references.pmid: 25528628
references.citation: Br J Pharmacol. 2004 Dec;143(7):819-26
references.pmid: 15492016
references.citation: Thromb Res. 2014 Nov;134(5):952-6
references.pmid: 25208456
references.citation: Cancer Res. 2014 Mar 15;74(6):1694-704
references.pmid: 24599131
references.citation: J Surg Res. 2009 Aug;155(2):183-90
references.pmid: 19645077
references.citation: Ann Surg. 2011 Apr;253(4):798-810
references.pmid: 21475023
references.citation: Platelets. 2013;24(6):462-8
references.pmid: 22871094
references.citation: Blood. 2012 Oct 4;120(14):2779-80
references.pmid: 23043025
references.citation: Anesthesiology. 2009 Jul;111(1):187-202
references.pmid: 19512862
references.citation: Semin Thromb Hemost. 2008 Mar;34(2):154-60
references.pmid: 18645920
references.citation: Nat Rev Cancer. 2011 Feb;11(2):123-34
references.pmid: 21258396
references.citation: Expert Rev Mol Diagn. 2013 Jul;13(6):581-99
references.pmid: 23895128
references.citation: Blood Coagul Fibrinolysis. 2010 Jul;21(5):406-13
references.pmid: 20614571
references.citation: Nat Rev Cancer. 2009 Apr;9(4):302-12
references.pmid: 19308069
references.citation: Drug Discov Ther. 2014 Oct;8(5):194-200
references.pmid: 25382553
references.citation: Surg Endosc. 2006 Jan;20(1):30-4
references.pmid: 16333547
references.citation: Ann Surg Oncol. 2008 Jul;15(7):2042-52
references.pmid: 18398660
references.citation: Expert Rev Anticancer Ther. 2008 Aug;8(8):1247-55
references.pmid: 18699763
references.citation: Thromb Res. 2014 May;133 Suppl 2:S149-57
references.pmid: 24862136
references.citation: Anesth Analg. 2010 Feb 1;110(2):531-40
references.pmid: 19910630